Sialidase NEU3 Contributes to the Invasiveness of Bladder Cancer

Takeo Tatsuta,Jun Ito,Koji Yamamoto,Shigeki Sugawara,Masahiro Hosono,Makoto Sato,Taeko Miyagi

DOI: https://doi.org/10.3390/biomedicines12010192

IF: 4.757

2024-01-17

Biomedicines

Abstract:Bladder cancer is the 10th most commonly diagnosed cancer worldwide. The current standard treatment for advanced bladder cancer is neoadjuvant cisplatin (NAC)-based chemotherapy followed by cystectomy. However, the response rate to chemotherapy is only 50%, owing to cisplatin resistance, and there is a need for novel therapies. Because the invasiveness of bladder cancer greatly influences patient prognosis, a mechanistic analysis of the invasive function can lead to therapeutic targets. Sialidases, which remove sialic acid residues from the nonreducing ends of sugar chains and catalyze the initial reaction in the degradation of sugar chains, are predicted to be involved in cell invasion and motility. However, the involvement of sialidases in bladder cancer, especially their relationship with the invasive ability, remains unclear. Here, using patient tissues and multiple bladder cancer cell lines, we show that the sialidase NEU3 is highly expressed in bladder cancer. Analysis of NEU3's function using its siRNA-mediated knockdown revealed that NEU3 contributes to bladder cancer invasiveness. Mechanistic analysis showed that NEU3 activates ERK and PI3K signaling. Our results show that NEU3 is involved in the malignancy of bladder cancer, and its suppression may lead to novel treatments for bladder cancer.

biochemistry & molecular biology,medicine, research & experimental,pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the invasiveness of bladder cancer. Specifically, the researchers focused on the role of a sialidase named NEU3 in bladder cancer. They found that NEU3 is highly expressed in bladder cancer tissues, and through siRNA - mediated knockdown experiments, it was proven that NEU3 significantly contributes to the invasive ability of bladder cancer cells. In addition, the study also explored the molecular mechanisms by which NEU3 affects cell invasiveness and found that NEU3 can activate the ERK and PI3K signaling pathways, thereby promoting the malignant progression of bladder cancer. Therefore, this study aims to reveal the role of NEU3 in the invasiveness of bladder cancer and its potential value as a therapeutic target.